Travis Mickle, CEO of KemPharm, talks about his company’s use of prodrugs, the business opportunities prodrugs represent, and how prodrugs are helping to improve patient centricity. The ...
Prodrug design in cancer chemotherapy encompasses the synthesis of inert precursors that undergo selective conversion into cytotoxic agents within the tumour milieu. Such strategies aim to enhance ...
The current interest in prodrugs is evident. Since 2008, the FDA has approved over 30 prodrugs, and approximately 10% of all marketed drugs worldwide can be considered prodrugs. Consequently, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results